UK MHRA grants marketing approval for Janssen─Cilag's Lazertinib for use in combination with amivantamab to treat adults ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has on 6th March, 2025, approved lazertinib (brand name Lazcluze) for adults with non-small cell lung cancer that has spread to other parts of the body and has undergone specific changes in …